Bajaj Healthcare Ltd

The company's financial performance has severely deteriorated. After peaking in FY21-FY22, both sales and profits have collapsed. Annual sales plummeted by 26.7% in FY24, reversing years of growth. The profit trajectory is more alarming, with net profit falling from a peak of ₹83 Cr in FY21 to a substantial net loss of ₹84 Cr in FY24. This loss was primarily caused by a large negative exceptional item of ₹114 Cr, which wiped out operating profits. Operating Profit Margins (OPM) have also compressed from a high of 21% in FY21 to 16% in FY24, indicating pressure on core profitability even before considering non-operating items. Quarterly results are highly volatile, with frequent fluctuations between profit and loss, underscoring earnings instability. This sharp reversal from strong growth to significant losses indicates fundamental challenges in operational and financial management.

Capital efficiency and returns have deteriorated significantly. Return on Capital Employed (ROCE) has been in a steep decline, falling from a high of 36% in FY21 to just 8% in FY24. This trend suggests that capital invested in the business is generating progressively lower returns. Similarly, Return on Equity (ROE) turned negative in FY24 due to the net loss, a sharp reversal from healthy double-digit returns in prior years. The efficiency of working capital management has also worsened considerably. The Cash Conversion Cycle (CCC) has elongated dramatically from a manageable 72 days (FY18-20 average) to an extended 217 days in FY24. This indicates that a significant amount of cash is tied up in operations, particularly in inventory (206 days) and receivables (139 days), posing a potential strain on liquidity. This combination of declining returns and inefficient working capital management is a major weakness.

The company's financial health is weak and shows signs of strain. Debt levels have risen substantially in recent years, pushing the Debt-to-Equity ratio from 0.51 in FY20 to 1.19 in FY24, indicating high financial leverage and elevated risk. While borrowings slightly decreased in FY24 from their peak in FY23, they remain high at ₹333 Cr. The most concerning metric is the Interest Coverage Ratio (PBIT/Interest), which has plummeted from a comfortable average of 10.8x during FY21-FY23 to a precarious 2.5x in FY24. This sharp decline, driven by falling profits and rising interest costs, indicates a severely diminished capacity to service its debt obligations from operating profits. This combination of high debt and rapidly falling debt-servicing capability points to a fragile financial position.

The shareholding structure presents a mixed picture. A significant positive is the high and stable promoter holding, which stood at 67.74% in March 2024. This demonstrates strong conviction from the management and aligns their interests with those of other shareholders. However, this is offset by a notable weakness: the extremely low level of institutional investment. As of March 2024, Foreign Institutional Investors (FIIs) and Domestic Institutional Investors (DIIs) held a combined stake of less than 1%. This suggests that the company has failed to attract sophisticated, long-term investors, which can be a negative signal regarding market perception of the company's governance, strategy, and future prospects. While promoter confidence is a strength, the absence of institutional validation is a major concern.

A significant accounting red flag is present in the company's FY24 results. The reporting of a massive exceptional item of -₹113.76 Cr single-handedly turned what would have been a small pre-tax loss into a deep net loss of ₹84 Cr. The absence of specific details in the provided data regarding the nature of such a large, one-off item is a major concern for transparency and raises questions about the quality and predictability of earnings. This event obscures the true underlying performance of the core business operations and introduces significant uncertainty into the financial statements.

The company faces high financial and solvency risk. This is evidenced by a Debt-to-Equity ratio of 1.19, which indicates that debt levels are greater than shareholder equity, signaling high leverage. More critically, the Interest Coverage Ratio has collapsed to just 2.5x in FY24. This low ratio means operating profits provide only a thin cushion to cover interest payments. This makes the company highly vulnerable to any further decline in profitability or increase in interest rates, elevating the risk of financial distress and default on its debt obligations.

Operational performance has weakened substantially, leading to heightened liquidity risk. The 27% year-on-year decline in sales in FY24 points to significant operational or market-related challenges. This is compounded by poor working capital management, as reflected in the extremely long Cash Conversion Cycle of 217 days. This means cash is tied up in operations for over seven months, primarily due to high inventory levels (206 days) and extended debtor collections (139 days). Such a long cycle puts a continuous strain on liquidity, potentially requiring further debt to fund day-to-day operations, especially in a period of declining sales and profitability.